In conclusion, the combination of PROTAC molecules targeting ABL1 in an allosteric manner and ATP-competitive TKIs provides a novel idea for the treatment of CML patients with highly resistant BCR::ABL1 mutations in clinical practice. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.